Lauren Riker is President & VP at Pacira BioSciences, Inc. (PCRX). They have made 3 open-market trades across 1 company since 2024, most recently 2026-10-08.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 62,284 | $2.3M |
Shares reported on the most recent Form 4, priced at the 2026-10-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | SELL · 10b5-1 | 2026-10-08 | 2026-10-09 | $36.32 | $218K | — | — | — |
| PCRX | SELL · 10b5-1 | 2026-06-11 | 2026-06-12 | $23.50 | $144K | +6.9% | +12.1% | +10.5% |
| PCRX | SELL | 2026-02-02 | 2026-02-03 | $20.81 | $83K | +3.0% | +8.1% | +16.8% |
| PCRX | SELL | 2026-01-05 | 2026-01-06 | $24.24 | $34K | -24.7% | -20.0% | -12.5% |
| PCRX | SELL | 2025-06-04 | 2025-06-05 | $26.21 | $292K | -8.6% | -13.0% | +1.9% |
| PCRX | SELL · 10b5-1 | 2024-06-12 | 2024-06-13 | $28.72 | $228K | -1.0% | -23.7% | -53.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.